Resistance of rumen bacteria murein to bovine gastric lysozyme by Domínguez-Bello, María G. et al.
BioMed CentralBMC Ecology
ssOpen AcceResearch article
Resistance of rumen bacteria murein to bovine gastric lysozyme
María G Domínguez-Bello*1,2, M Andreína Pacheco2, Marie C Ruiz2, 
Fabián Michelangeli2, Matthias Leippe3 and Miguel A de Pedro4
Address: 1Dept. Biology, University of Puerto Rico, Rio Piedras Campus, PO Box 23360, San Juan Puerto Rico 00931, 2Instituto Venezolano de 
Investigaciones Científicas, Centro de Biofísica y Bioquímica, A. postal 21827, Caracas 1020A, Venezuela, 3Bernhard Nocht Institute for Tropical 
Medicine, Hamburg, Germany and 4Laboratorio de Envolturas Bacterianas, Centro de Biología Molecular Severo Ochoa, CSIC, UAM, Madrid, 
Spain
Email: María G Domínguez-Bello* - mgdbello@cnnet.upr.edu; M Andreína Pacheco - apacheco@ivic.ve; Marie C Ruiz - mclr@ivic.ve; 
Fabián Michelangeli - fabian@ivic.ve; Matthias Leippe - matthias.leippe@mail.uni-wuerzburg.de; Miguel A de Pedro - madepedro@cbm.uam.es
* Corresponding author    
Abstract
Background: Lysozymes, enzymes mostly associated with defence against bacterial infections, are
mureinolytic. Ruminants have evolved a gastric c type lysozyme as a digestive enzyme, and profit
from digestion of foregut bacteria, after most dietary components, including protein, have been
fermented in the rumen. In this work we characterized the biological activities of bovine gastric
secretions against membranes, purified murein and bacteria.
Results: Bovine gastric extract (BGE) was active against both G+ and G- bacteria, but the effect
against Gram- bacteria was not due to the lysozyme, since purified BGL had only activity against
Gram+ bacteria. We were unable to find small pore forming peptides in the BGE, and found that
the inhibition of Gram negative bacteria by BGE was due to an artefact caused by acetate. We
report for first time the activity of bovine gastric lysozyme (BG lysozyme) against pure bacterial
cultures, and the specific resistance of some rumen Gram positive strains to BGL.
Conclusions: Some Gram+ rumen bacteria showed resistance to abomasum lysozyme. We
discuss the implications of this finding in the light of possible practical applications of such a stable
antimicrobial peptide.
Background
Lysozymes are beta-N-acetyl-muramyl-hydrolase that dis-
rupt bacterial murein [1]. The most common animal lys-
ozyme is the c type, such as the chicken egg white
lysozyme (EWL, 14.3 Kda), found in animal, insects and
plants [2]. Monogastric animals possess a single gene for
lysozyme c expressed in various tissues [3] and is thought
to be primarily involved in defence against bacterial
infections.
In contrast, ruminants have multiple lysozyme genes [4],
and at least four code for a gastric lysozyme that functions
as a digestive enzyme. Most dietary components are fer-
mented in the rumen to volatile fatty acids [5], and the
ruminant benefits of digesting foregut bacteria as a source
of amino acids. Cow gastric lysozyme is a basic enzyme
adapted to act in the harsh gastric conditions, with opti-
mal activity at low pH (4.5–5.2), low ionic strength val-
ues, and resistant to acid and pepsin [6,7]. We have
previously reported that the recruitment of lysozyme as a
gastric digestive enzyme has convergently occurred in the
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gene duplication events during its evolution [9]. Amino
acid differences between homologous proteins from dif-
ferent species may have adaptive significance, as is the
case with gastric lysozymes. Lysozymes from the stomachs
of cows and langur monkeys (both with fermentation in
the foregut) are subject to positive darwinian selection
[10,11].
Rumen bacteria represent an important component of the
rumen biomass [5] and is a likely factor exerting evolu-
tionary pressure on gastric lysozyme and other gastric
secretions in herbivores with foregut fermentation. This
prompted us establish 2 hypotheses: 1 – there might be
other abomasum peptides with antimicrobial activity in
addition to lysozyme, that would also act against Gram
negative bacteria; 2 – since rumen bacteria have been sub-
ject to the selective pressure of gastric antimicrobial secre-
tions, rumen bacteria might have developed resistance to
these compounds. The objective of this work was to char-
acterize the biological activities of bovine gastric secre-
tions against membranes, purified murein and bacteria.
Results
Cow abomasum mucosa yielded 26.4 mg BGE per g of tis-
sue (1.32 g, of lyophilized extract per 100 ml of acetic
extract from 50 g wet mucosa, sd 0.61, N = 20). Protein
content of extracts was 60%, equivalent to 16 mg protein
per gram of gastric tissue. A total of 5 g of gastric extract
was subject to chromatography, and 82,2 mg of active
(lytic) protein were obtained. This represents a yield of
1.64% w/w of lysozyme from the crude extract, and 0.43
mg of lysozyme per gram of tissue.
SDS-PAGE of the bovine gastric extract revealed a major
protein band of about 15 Kda and two other bands of big-
ger proteins (30 and 45 Kda). Non denaturing electro-
phoresis showed the protein band with lytic activity on M.
luteus-embedded overlay gel, presumably gastric lys-
ozyme. Lysis of M. luteus suspension by the gastric extract
is shown in Fig. 1. Specific activity (on M. luteus) of the
extract from the whole gastric mucosa was 3.40 U (sd
1.48, N = 20) at pH 5.5. Specific activity of the gastric
extract decreased 32% at pH 6 (2.42 U) and 42% at pH 6.5
(2.04 U). Extract specific activity at pH 5.5 was higher in
the extract of gastric fundus (4.39 U) than in that of the
antrum and body (2.49 U and 2.34 U, respectively).
BGE was bacteriolytic against M. luteus in a concentration-
dependent manner (Fig 1). BGE also degraded Murami-
dase E. coli murein, producing a different profile to that of
the fungal lysozyme cellosyl (Fig 2). Muropeptides have a
basic structure consisting of N-acetylglucosaminyl-N-
acetylmuramyl-L-Ala-D-Glu-gamma-mDap-R1R2, where
R1 and R2 are substituents at the L-carboxy and D-amino
groups. BGE (500 µg/ml) produced different muropep-
tides to those produced by cellosyl (50 µg/ml), including
the lack of a peak at minute 27 (muropeptide with R1 =
D-Ala and R2 = -H) that was produced by treatment with
cellosyl. This peak was eluted and incubated with both
BGE and cellosyl. BGE further digested this muropeptide
(Fig 2c) while cellosyl did not (Fig 2d). This suggests hat
unlike cellosyl, BGE lysozyme has L, D carboxypeptidase
or Nacetyl muramyl L-ala amidase activity.
BGE was active against P. aeruginosa and E. coli, permeabi-
lized vesicles and depolarized liposomes. These activities
were screened in isolated proteins and small peptides
yielding no active peptides from the BGE extract, includ-
ing BGL, inactive against Gram negative bacteria (Table
1). Permeabilizing activity proved to be due to acetate in
the gastric extract, since BSA resuspended in acetic acid
and lyophilized had similar activity to BGE. BGL not
inhibit the growth of some Gram positive rumen bacteria
such as L. acidophilus and S. bovis, which were highly
inhibited by EWL, indicating specific resistance of the
rumen bacteria murein to BGL (Table 1).
Discussion
Muramidase activity in the acid stomach of a foregut fer-
menter, receiving a considerable biomass of bacteria,
allows the digestion of bacterial cell walls and liberalisa-
tion of amino acid-rich cell contents. The activity of BG
lysozyme on purified murein was different to that of other
c lysozymes in having lower optimal pH and L, D carbox-
ypeptidase or Nacetyl muramyl L-ala amidase activity. It
was, like other lysozymes, active only against Gram posi-
tive bacteria. Other systems such as Entamoeba histolytica,
are known to contain lysozyme acting in concert with
membrane permeabilizing peptides [12], but attempts to
purify active small peptides from BGE have failed, so far.
Presence of Gram negative bacteria in the rumen does not
seem to have driven the evolution of gastric peptides capa-
ble of degrade them. This would limit the efficiency of the
system, since only Gram positive bacteria are amenable to
digestion, and Gram negative bacteria represent a consid-
erable proportion of rumen bacterial biomass. Further-
more, some rumen Gram positive bacteria seem to have
developed resistance to the action of BG lysozyme.
Rumen bacterium Streptococcus bovis can develop resist-
ance to the pore-forming peptide nisin, by modifying cell
lipoteichoic acids. Acquisition of nisin resistance also con-
ferred lysozyme resistance [13]. Little is known about bac-
teria developing resistance to lysozymes from the host
they colonize, as in the case of rumen bacteria and gastric
bovine lysozyme. The phenomenon might reflect the
selective pressure of the gastric enzyme on rumen bacteria,
since BGL-resistant bacteria will be more likely to colonizePage 2 of 6
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sensitive strains.
The search for new antibacterial drugs has lead to explore
more speculative approaches to destroy or inhibit patho-
gen microorganisms and viruses. It is tempting to optimis-
tically predict that highly stable peptides that naturally
evolved as gastric antimicrobials may have a high poten-
tial for clinical applications. Human lysozyme (secreted
by monocytes), while playing a protective role against
infections, depresses superoxide generation of neutro-
phyls and enhances lymphocyte proliferative response
[14-17]. EWL has been applied against bacterial and viral
infections, based on its immune-stimulation and anti-
inflammatory properties [18].
Ruminant BG lysozymes, having evolved in a very hostile
environment such as the stomach, have developed resist-
ance to acid and proteolysis, and may hold promising
uses in treating infections, and in the food industry. In the
animal production industry, the uses of antibiotics and
hormones as growth promoters has posed health threats
to humans and animals, and feed supplementation with
some growth promoters is now illegal. The use of new
growth promoters that don't pose problems of resistance
is a priority, and antimicrobial peptides are of course good
candidates. Indeed, lysozyme has been found to be as
effective as conventional antibiotics, in promoting growth
of poultry [19]. However, the discovery of the capacity of
bacteria to presumably modify its bacterial murein and
become resistant to the lytic action of lysozymes, will
Bacteriolytic activity of gastric extract against M. luteusFigure 1
Bacteriolytic activity of gastric extract against M. luteus. Lytic activity shown as % of initial scattering of a M. luteus suspension 
(0.25 mg/ml in acetate buffer pH 5.5) treated (indicated by arrow) with gastric extracts of whole abomasum mucosa (E1, E2, 
E3, E4 and E, corresponding to extract concentrations of 42, 133, 233, 417 and 554 µg/ml, respectively) and EWL (5 µg/ml).
0 50 100 150 200 250 300 350 400
0
20
40
60
80
100
EWL
E,4
E,5
E,3
E,2
E1
%
 
Sc
at
te
rin
g
Time (seconds)Page 3 of 6
(page number not for citation purposes)
BMC Ecology 2004, 4 http://www.biomedcentral.com/1472-6785/4/7Muramidase activity of gastric extract on Echerichia coli purified mureinFigure 2
Muramidase activity of gastric extract on Echerichia coli purified murein. Muropeptide profile after digestion of murein with gas-
tric extract (500 µg/ml, a) or with the fungal muramidase cellosyl (50 ug/ml, b). Cellosyl produced a tetrapeptide at 27 min cor-
responding to M4 (having R1 = D-Ala and R2 = -H). This was further digested by gastric extract (500 ug/ml, c) but not by 
cellosyl (50 ug/ml, d).
Table 1: Percentage of growth of control cultures at 6 hours, of Gram+ and Gram- bacteria grown in the presence of EW lysozyme, BG 
lysozyme and BGE.
ORIGIN BACTERIUM Egg White 
Lysozyme 
150 ug/ml
Bovine Gastric 
Lysozyme 
150 ug/ml
Bovine Gastric 
Extract 
10 mg/ml
pH 5.5 pH 7.0 pH 5.5 pH 7.0 pH 5.5 pH 7.0
ENVIRONMENTAL, INTESTINAL Gram positive M. luteus lysed1 lysed1 lysed1 lysed1 lysed1 lysed1
Gram negative P. aeruginosa 106 173 142 182 0 90
E. coli 103 91 86 124 15 44
RUMEN Gram positive L. vitulinus 1 4 81 69 10 8
L. acidophilus 0 NG 64 NG 168 NG
S. bovis 101 6 108 114 98 111
Gram negative S. ruminantium 109 112 130 96 89 87
P. ruminicola NG 24 NG 113 NG 208
1 = cells lysed by treatment in scattering assay. Italic bold numbers = growth inhibited. NG = no growth of culture at this pH.
16  20  27 30   43   51  56  60   70  min
a
b
16   27 30   min
c
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terial antibiotic resistance.
Conclusions
This work shows that gastric bovine lysozyme is active
against Gram positive bacteria but that some rumen
strains are unaffected by the enzyme. Possible practical
applications of this antimicrobial peptide as an alternative
to antibiotics may be limited by the development of bac-
terial resistance to the lytic action of lysozymes.
Methods
Gastric extract and lysozyme purification
Acetic acid extract from abomasal mucosa was prepared as
described by Dobson et al. [7]. Bovine gastric extracts
(BGE) were lyophilised and kept frozen. BGE proteins
were separated by denaturing and non-denaturing PAGE
electrophoresis. Band lytic activity was revealed on an
overlaying agarose gel embedded with M. luteus. Purifica-
tion of BG lysozyme was performed re-dissolving
lyophilised BGE in 10 vol. of 10% acetic acid, centrifuging
at 150,000 × g at 4°C for 1 h. The resulting supernatant,
was diluted 1:2.5 with 20% acetonitrile/0.08% trifluoro-
acetic acid. The material was passed in 0.5 ml batches over
a Superdex Pep 10/30 column (Pharmacia LKB)
equilibrated with 20% acetonitrile/0.08% trifluoroacetic
acid at 20°C and a flow rate of 0.1 ml/min. Active frac-
tions were pooled, diluted 1:2 with starting buffer (50
mM sodium-acetate, pH 4.5) and loaded onto a Mono S
5/5 cation-exchange column (Pharmacia LKB) equili-
brated with starting buffer. Adsorbed protein was eluted
by washing the column with the same buffer (5 ml) and
by use of a 0–500 mM NaCl gradient (15 ml) and a final
wash of 1 M NaCl at 10°C. Active material was diluted
1:13 with starting buffer (50 mM sodium-acetate, pH 7.8)
and applied again to a Mono S HR 5/5 column (Pharma-
cia LKB) equilibrated with starting buffer. The column was
washed with the same buffer (5 ml) and developed with a
15-ml gradient of 0–500 mM NaCl at 10°C. Active frac-
tions were pooled and stored at -20°C. Reversed-phase
HPLC was performed on an Aquapore Butyl 300 column
(2.1 × 30 mm; Brownlee Labs) connected with a 130 A
separation system (Applied Biosystems). Elution was
done with a linear gradient of 0–84% acetonitrile in 0.1%
trifluoroacetic acid at 30°C over 45 min. A flow rate of 0.2
ml min-1 was applied, the effluent was monitored by
absorbance at 214 nm. Peak fractions were collected man-
ually and tested immediately for lysozyme activity using
the lysoplate technique [20]. Tricine-SDS electrophoresis
was performed in 13% separation gels [21].
Antimicrobial tests
Lytic activity against M. luteus was determined by scatter-
ing changes in a suspension of Micrococcus luteus (0.25
mg/ml in acetate buffer) [8]. Egg white (EW) lysozyme
(Sigma) was used as a control. Specific activity per ug of
gastric extract was defined as units of activity of 1 ng of
EWL on M. luteus, at pH 5.5. Inhibitory effect on bacterial
growth was determined on broth and agar lysoplates [20].
Microdilution susceptibility test [22] was used to deter-
mine minimal inhibitory concentrations. Effect of BGE or
BG lysozyme on bacterial growth was determined in broth
cultures in which growth was monitored turbidimetrically
(A600 nm).
Muramidase activity of BGE was assayed on purified E. coli
murein [23] with cellosyl (Hoechst, Frankfurt am Main;
50 µg/ml) and gastric extract (500 µg/ml), determining by
HPLC the production of soluble low molecular weight
muropeptides [24]. A control without murein was
included in the runs and gave no peaks. When required,
produced muropeptides were collected individually at the
UV detection outlet, vacuum dried, resuspended in MilliQ
water and desalted as previously described [23].
Membrane-permeabilyzing activity of gastric extracts was
determined fluorimetricaly, by the liberation of carboxy-
fluorescein (CF) from brush border membrane vesicles
from pig intestinal brush border [25] and by dissipation
of a valinomycin-induced diffusion potential in lipo-
somes [26].
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